
Metagenomi Inc (MGX) Stock Forecast & Price Target
Metagenomi Inc (MGX) Analyst Ratings
Bulls say
Metagenomi Therapeutics Inc. is recognized for its innovative approach to genetic medicine, utilizing a proprietary metagenomics-derived genome editing toolbox that includes advanced systems like programmable nucleases and CRISPR-associated transposases. The company has demonstrated significant progress in its pipeline, achieving durable factor VIII (FVIII) levels of 80% over a 19-month period in preclinical models for disorders such as Hemophilia A, underscoring the effectiveness of its gene editing technology. The strategic focus on vivo gene editing for its wholly-owned pipeline, alongside pursuing technology out-licensing opportunities for ex vivo cell therapy, positions Metagenomi favorably for future growth and revenue potential.
Bears say
Metagenomi Therapeutics reported a net loss of $19.9 million in its 2Q25 financial results, translating to a loss of $0.54 per share. The company is also trading significantly below cash, highlighting potential upside; however, this position is overshadowed by substantial risks, including possible delays in clinical assessments and the failure to produce favorable data from key pipeline candidates. Furthermore, there is a looming concern regarding long-term dilution risk, contributing to a primarily negative outlook on the company's financial health and stock performance.
This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.
Metagenomi Inc (MGX) Analyst Forecast & Price Prediction
Start investing in Metagenomi Inc (MGX)
Order type
Buy in
Order amount
Est. shares
0 shares